JP2013542247A5 - - Google Patents

Download PDF

Info

Publication number
JP2013542247A5
JP2013542247A5 JP2013538301A JP2013538301A JP2013542247A5 JP 2013542247 A5 JP2013542247 A5 JP 2013542247A5 JP 2013538301 A JP2013538301 A JP 2013538301A JP 2013538301 A JP2013538301 A JP 2013538301A JP 2013542247 A5 JP2013542247 A5 JP 2013542247A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
compound according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538301A
Other languages
English (en)
Japanese (ja)
Other versions
JP5902704B2 (ja
JP2013542247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054852 external-priority patent/WO2012066442A1/en
Publication of JP2013542247A publication Critical patent/JP2013542247A/ja
Publication of JP2013542247A5 publication Critical patent/JP2013542247A5/ja
Application granted granted Critical
Publication of JP5902704B2 publication Critical patent/JP5902704B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538301A 2010-11-15 2011-11-01 Hiv複製の阻害剤 Expired - Fee Related JP5902704B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41361810P 2010-11-15 2010-11-15
US61/413,618 2010-11-15
US201161485355P 2011-05-12 2011-05-12
US61/485,355 2011-05-12
PCT/IB2011/054852 WO2012066442A1 (en) 2010-11-15 2011-11-01 Inhibitors of hiv replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016046384A Division JP2016164163A (ja) 2010-11-15 2016-03-10 Hiv複製の阻害剤

Publications (3)

Publication Number Publication Date
JP2013542247A JP2013542247A (ja) 2013-11-21
JP2013542247A5 true JP2013542247A5 (enExample) 2014-12-18
JP5902704B2 JP5902704B2 (ja) 2016-04-13

Family

ID=44999830

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538301A Expired - Fee Related JP5902704B2 (ja) 2010-11-15 2011-11-01 Hiv複製の阻害剤
JP2016046384A Pending JP2016164163A (ja) 2010-11-15 2016-03-10 Hiv複製の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016046384A Pending JP2016164163A (ja) 2010-11-15 2016-03-10 Hiv複製の阻害剤

Country Status (15)

Country Link
US (3) US8809363B2 (enExample)
EP (1) EP2640729B1 (enExample)
JP (2) JP5902704B2 (enExample)
CN (2) CN105330675A (enExample)
AR (1) AR083870A1 (enExample)
AU (2) AU2011330850B2 (enExample)
BR (1) BR112013011991A2 (enExample)
CA (1) CA2817896A1 (enExample)
CL (1) CL2013001338A1 (enExample)
MX (1) MX343274B (enExample)
RU (1) RU2564445C2 (enExample)
TW (1) TWI445709B (enExample)
UY (1) UY33729A (enExample)
WO (1) WO2012066442A1 (enExample)
ZA (1) ZA201303433B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
BR112012033689A2 (pt) 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
AU2011274322B2 (en) 2010-07-02 2015-08-13 Gilead Sciences, Inc. Naphth- 2 -ylacetic acid derivatives to treat AIDS
NZ610315A (en) 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
AU2011330850B2 (en) * 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
EA024952B1 (ru) 2011-04-21 2016-11-30 Джилид Сайэнс, Инк. Бензотиазолы и их применение для лечения вич-инфекции
WO2013062028A1 (ja) 2011-10-25 2013-05-02 塩野義製薬株式会社 Hiv複製阻害剤
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
ES2668422T3 (es) 2012-04-20 2018-05-18 Gilead Sciences, Inc. Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Hiv複製抑制劑
EP2970273B1 (en) 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970301B1 (en) 2013-03-13 2017-01-11 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP2970298A1 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2970274B1 (en) 2013-03-14 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9540393B2 (en) 2013-03-14 2017-01-10 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CA2916504A1 (en) 2013-06-25 2014-12-31 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
US9944656B2 (en) 2014-02-12 2018-04-17 VIIV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126758A1 (en) 2014-02-18 2015-08-27 Bristol-Myers Squibb Company Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
EP3107913B1 (en) 2014-02-19 2018-07-04 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP6579549B2 (ja) 2014-05-16 2019-09-25 塩野義製薬株式会社 Hiv複製阻害作用を有する3環性複素環誘導体
EA031614B1 (ru) 2014-10-24 2019-01-31 Бристол-Майерс Сквибб Компани Трициклические атропоизомерные соединения
HUE050592T2 (hu) 2014-10-24 2020-12-28 Bristol Myers Squibb Co Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként
MA40302B1 (fr) 2014-10-24 2018-10-31 Bristol Myers Squibb Co Dérivés de carbazole
US10806734B2 (en) 2015-05-08 2020-10-20 Katholieke Universiteit Leuven Functional cure of retroviral infection
WO2016194806A1 (ja) 2015-05-29 2016-12-08 塩野義製薬株式会社 Hiv複製阻害作用を有する含窒素3環性誘導体
CN111018912A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种抗病毒药物关键中间体的合成和纯化方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5489586A (en) * 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7112594B2 (en) * 2000-08-09 2006-09-26 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
JP2003171381A (ja) 2001-09-25 2003-06-20 Takeda Chem Ind Ltd エントリー阻害剤
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Hiv阻害剤
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
WO2003047564A1 (en) 2001-12-05 2003-06-12 Shionogi & Co., Ltd. Derivative having hiv integrase inhibitory activity
CA2469592C (en) 2001-12-12 2005-08-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
ATE516029T1 (de) 2001-12-21 2011-07-15 Tibotec Pharm Ltd Sulfonamide die ein heterozyklus-substituiertes phenyl enthalten als broadspectrum-hiv-protease- inhibitoren
AU2003216049B2 (en) 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
WO2005076861A2 (en) * 2004-02-04 2005-08-25 University Of Virginia Patent Foundation Compounds that inhibit hiv particle formation
ATE430751T1 (de) * 2004-12-17 2009-05-15 Hoffmann La Roche Thienopyridinderivate als allostere gaba-b- enhancer
CA2705312C (en) * 2007-11-15 2013-06-25 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
RU2402531C2 (ru) * 2008-09-24 2010-10-27 Александр Леонидович Гинцбург Биологически активные вещества, подавляющие патогенные бактерии
GB0908394D0 (en) * 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US20120316161A1 (en) 2009-12-23 2012-12-13 Katholieke Universiteit Leuven Novel antiviral compounds
AU2011330850B2 (en) * 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
NZ610315A (en) 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
AU2012209373A1 (en) 2011-01-24 2013-04-11 Glaxosmithkline Llc Isoquinoline compounds and methods for treating HIV
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びhivを治療するための方法

Similar Documents

Publication Publication Date Title
JP2013542247A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013518107A5 (enExample)
JP2014521735A5 (enExample)
JP2012255026A5 (enExample)
JP2013509429A5 (enExample)
JP2012532874A5 (enExample)
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2012502037A5 (enExample)
JP2013014622A5 (enExample)
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
JP2009502743A5 (enExample)
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2013525444A5 (enExample)
JP2013534248A5 (enExample)
JP2013520405A5 (enExample)
JP2009102342A5 (enExample)
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
JP2007145875A5 (enExample)
JP2010077141A5 (enExample)
HRP20171512T1 (hr) Derivati betulina
JP2013542261A5 (enExample)
JP2016510326A5 (enExample)
JP2015509075A5 (enExample)